Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02672423 · ClinicalTrials.gov registry record · Phase 1
A Study of Abemaciclib in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT02672423 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 127 participants.
The verdict
NCT02672423, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is to measure how much abemaciclib gets into the blood stream and how long it takes the body to get rid of it when given as capsules versus a tablet(s). The effect of a high fat meal on the tablet formulation will also be evaluated. In addition, the tolerability of abemaciclib tablet and capsule formulations will be evaluated. Information about any side effects that may occur will also be collected. This study has 3 parts. Parts A and C will last about 44 days including follow-up. Part B will last about 60 days including follow-up. Screening may occur up to 28 days before the first dose of study drug. Participants are only allowed to enroll in one part. This study is for research purposes only and is not intended to treat any medical condition.
Interventions
- DRUG Abemaciclib Capsules (Reference Formulation)
- DRUG Abemaciclib Tablet (Test Formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02672423
The ClinicalTrials.gov registry entry for NCT02672423 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abemaciclib Capsules (Reference Formulation) is the first listed.
NCT02672423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02672423 about?
NCT02672423 is a clinical study titled "A Study of Abemaciclib in Healthy Participants". The purpose of this study is to measure how much abemaciclib gets into the blood stream and how long it takes the body to get rid of it when given as capsules versus a tablet(s). The effect of a high fat meal on the tablet formulation will also be evaluated. In addition, the tolerability of abemacic...
What is the current status of trial NCT02672423?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2016-02. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02672423?
The interventions under investigation include: Abemaciclib Capsules (Reference Formulation) (DRUG), Abemaciclib Tablet (Test Formulation) (DRUG).
Who is sponsoring clinical trial NCT02672423?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.